A new study is offering encouraging news for people living with BRAF V600E-mutant metastatic colorectal cancer (mCRC), a subtype of colorectal cancer (CRC) that can be especially difficult to treat.
Results from the phase III BREAKWATER clinical trial found that a targeted treatment combination using encorafenib (Braftovi), cetuximab (Erbitux), and chemotherapy significantly improved progression-free survival (PFS) compared with standard chemotherapy alone. Progression-free survival refers to the length of time a treatment can keep cancer from growing or spreading.
Researchers say these findings may help change the standard of care for some patients newly diagnosed with this type of mCRC.
What is BRAF V600E-mutant metastatic colorectal cancer?
BRAF is a gene that helps control how cells grow. In some CRCs, a specific mutation called BRAF V600E causes cancer cells to grow and spread more aggressively.
Up to 12% of mCRCs carry this mutation. Patients with BRAF V600E-mutant disease often have fewer treatment options and may not respond as well to standard chemotherapy alone.
Because of this, researchers have been studying targeted therapies designed specifically to block the abnormal BRAF pathway.
What did the BREAKWATER trial study?
The BREAKWATER trial evaluated whether adding targeted therapy to chemotherapy could improve outcomes for patients with previously untreated BRAF V600E-mutant mCRC.
The study tested a combination of:
- Encorafenib (Braftovi), a BRAF inhibitor
- Cetuximab (Erbitux), an EGFR-targeted therapy
- FOLFIRI chemotherapy
Researchers compared this treatment approach with standard FOLFIRI chemotherapy, with or without bevacizumab (Avastin).
The study included 147 patients with newly diagnosed mCRC with the BRAF V600E mutation.
What were the results?
The targeted treatment combination significantly improved progression-free survival compared with standard chemotherapy.
Researchers also saw higher response rates in patients who received the encorafenib-based combination:
- 64.4% of patients responded to treatment in the targeted therapy group
- 39.2% responded in the standard treatment group
Some patients even experienced complete responses, meaning no detectable cancer could be found on scans:
- 4.1% in the targeted therapy group
- 1.4% in the standard treatment group
Responses also tended to last longer with the targeted approach. More than half of responders receiving the encorafenib combination maintained their response for at least 6 months.
Importantly, benefits were seen across different age groups, including patients younger than 65 and those 65 and older.
Although overall survival data are still early, researchers reported a positive trend favoring the encorafenib combination.
Why are these findings important?
These results build on earlier research showing benefits from encorafenib-based treatment strategies in BRAF V600E-mutant colorectal cancer.
In December 2024, the combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy received accelerated approval for patients with previously untreated BRAF V600E-mutant mCRC. The BREAKWATER findings provide additional evidence that combining targeted therapy with chemotherapy may help patients live longer without their cancer progressing.
What side effects were reported?
The safety profile of the treatment combination was generally consistent with the known side effects of the medications involved.
The most common side effects included:
- Nausea
- Diarrhea
- Vomiting
Serious side effects occurred at similar rates in both treatment groups, and relatively few patients had to stop treatment because of side effects.
Researchers reported no new safety concerns during the study.
What does this mean for patients?
For patients newly diagnosed with BRAF V600E-mutant mCRC, these findings may represent an important step forward.
Targeted therapies are helping doctors move toward more personalized treatment approaches based on the genetic makeup of a tumor. Testing for biomarkers like BRAF mutations can help identify treatments that may be more effective for certain patients.
If you or a loved one has mCRC, it’s worth discussing biomarker testing and targeted therapy options with your care team to better understand what treatments may be available.
Connect with an Outcomes4Me oncology nurse practitioner at no charge through the Outcomes4Me app, using the “Ask Outcomes4Me” button.
